Interleukin-6 inhibition in ST-elevation myocardial infarction: Immune cell profile in the randomised ASSAIL-MI trial

BACKGROUND: We recently showed that interleukin (IL)-6 inhibition by tocilizumab improves myocardial salvage in ST-elevation myocardial infarction (STEMI). However, the mechanisms for this effect are not clear. METHODS: In this exploratory sub-study of the ASSAIL-MI trial, we examined leukocyte diff...

Descripción completa

Detalles Bibliográficos
Autores principales: Huse, Camilla, Anstensrud, Anne Kristine, Michelsen, Annika E., Ueland, Thor, Broch, Kaspar, Woxholt, Sindre, Yang, Kuan, Sharma, Kapil, Tøllefsen, Ingvild Maria, Bendz, Bjørn, Amundsen, Brage Høyem, Damås, Jan Kristian, Berg, Erlend Sturle, Bjørkelund, Elisabeth, Quiles-Jiménez, Ana, Bjerkeli, Vigdis, Bendz, Christina, Kleveland, Ola, Stensaeth, Knut Haakon, Opdahl, Anders, Kløw, Nils-Einar, Andersen, Geir Øystein, Wiseth, Rune, Halvorsen, Bente, Gullestad, Lars, Seljeflot, Ingebjørg, Aukrust, Pål, Osnes, Liv, Dahl, Tuva B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9079006/
https://www.ncbi.nlm.nih.gov/pubmed/35504178
http://dx.doi.org/10.1016/j.ebiom.2022.104013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9079006/
https://www.ncbi.nlm.nih.gov/pubmed/35504178
http://dx.doi.org/10.1016/j.ebiom.2022.104013

Ejemplares similares